Fig. 5: IPI549@HMP-augmented RT against postsurgical tumor progression. | Nature Communications

Fig. 5: IPI549@HMP-augmented RT against postsurgical tumor progression.

From: Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis

Fig. 5

a Schematic illustration of the experiment design to assess the in vivo IPI549@HMP-based RT and its triggered immune responses. b Representative bioluminescence images of Luc+ CT26 tumor after varied treatments as indicated (n = 6 mice). c-f Average tumor growth curves (c), individual tumor growth kinetics (d), Kaplan-Meier survival curves (e) and body weight fluctuation curves (f) of CT26 tumor-bearing mice after varied therapeutic combinations (n = 6 mice in c-f). g Western blot analysis of p110γ in residual tumors collected from mice in different groups. The experiments were repeated three times. h Representative immunofluorescence images from three biologically independent samples of tumor slices stained with DAPI (blue), CRT (red) and HMGB1 (green) antibodies. SR, surgical resection; RT, radiotherapy; CRT, calreticulin; HMGB1, high mobility group box 1. Statistical difference was calculated using two-tailed unpaired student’s t-test (c) and Log-rank (Mantel-Cox) test (e). Data were expressed as means ± SD (c, f). *P < 0.05, **P < 0.01 and ***P < 0.001. Source data are provided as a Source Data file.

Back to article page